Spruce Biosciences (SPRB) to Release Quarterly Earnings on Wednesday

Spruce Biosciences (NASDAQ:SPRB) is anticipated to release its earnings data before the market opens on Wednesday, March 12th. Analysts expect Spruce Biosciences to post earnings of ($0.28) per share and revenue of $0.89 million for the quarter.

Spruce Biosciences Stock Performance

Shares of SPRB stock opened at $0.35 on Tuesday. Spruce Biosciences has a 12 month low of $0.34 and a 12 month high of $5.53. The firm has a market capitalization of $14.41 million, a PE ratio of -0.37 and a beta of 2.34. The firm has a fifty day simple moving average of $0.39 and a two-hundred day simple moving average of $0.45. The company has a current ratio of 5.36, a quick ratio of 5.36 and a debt-to-equity ratio of 0.01.

Analyst Upgrades and Downgrades

SPRB has been the subject of several analyst reports. Citizens Jmp downgraded Spruce Biosciences from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, December 11th. Royal Bank of Canada restated a “sector perform” rating and set a $1.50 price objective (down from $2.00) on shares of Spruce Biosciences in a research note on Wednesday, December 11th. Guggenheim reaffirmed a “neutral” rating on shares of Spruce Biosciences in a report on Thursday, December 12th. JMP Securities reiterated a “market perform” rating and issued a $3.00 target price on shares of Spruce Biosciences in a report on Wednesday, December 11th. Finally, Oppenheimer restated a “market perform” rating on shares of Spruce Biosciences in a report on Wednesday, December 11th. Nine analysts have rated the stock with a hold rating, According to data from MarketBeat, Spruce Biosciences currently has an average rating of “Hold” and a consensus target price of $2.38.

About Spruce Biosciences

Spruce Biosciences, Inc, a biopharmaceutical company, focuses on developing and commercializing novel therapies for rare endocrine disorders. The company engages in developing tildacerfont, a non-steroidal therapy to enhance disease control and reduce steroid burden for patients suffering from congenital adrenal hyperplasia (CAH), which is in Phase 2b clinical trial; and to evaluate glucocorticoid reduction in adult patients with classic CAH that is Phase 2b clinical trial.